MedTrace Logo

Effect of YAP1-inhibition in Surgical Wounds.

NCT06944249 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-25

No results posted yet for this study

Summary

When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent.

A good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process.

Our study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis.

We are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this.

Will verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.

Conditions

  • Scar Formation

Interventions

DRUG

NaCl (placebo)

During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.

DRUG

Verteporfin Injection

During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.

Sponsors & Collaborators

  • University of Geneva, Switzerland

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • Jöri Pünchera

    lead OTHER

Principal Investigators

  • Jöri Pünchera, M.D. · University Hospital, Geneva

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-08
Primary Completion
2026-04-30
Completion
2026-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06944249 on ClinicalTrials.gov